Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 435745, 8 pages
http://dx.doi.org/10.1155/2010/435745
Review Article

Cytokine-Induced NK-Like T Cells: From Bench to Bedside

1Department of Haematology, Singapore General Hospital, Singapore 169608
2Division of Cellular and Molecular Research, Humphrey Oei Institute of Cancer Research, National Cancer Center Singapore, 11 Hospital Drive, Singapore 169610

Received 19 November 2009; Accepted 4 February 2010

Academic Editor: Hanchun Yang

Copyright © 2010 Yeh Ching Linn and Kam M. Hui. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. A. Grimm, A. Mazumder, H. Z. Zhang, and S. A. Rosenberg, “Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes,” Journal of Experimental Medicine, vol. 155, no. 6, pp. 1823–1841, 1982. View at Google Scholar · View at Scopus
  2. J. H. Phillips and L. L. Lanier, “Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis,” Journal of Experimental Medicine, vol. 164, no. 3, pp. 814–825, 1986. View at Google Scholar · View at Scopus
  3. A. C. Ochoa, G. Gromo, B. J. Alter, P. M. Sondel, and F. H. Bach, “Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, β-IL 1, interferon-γ and -β,” Journal of Immunology, vol. 138, no. 8, pp. 2728–2733, 1987. View at Google Scholar · View at Scopus
  4. R. Lafreniere and S. A. Rosenberg, “Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2,” Cancer Research, vol. 45, no. 8, pp. 3735–3741, 1985. View at Google Scholar · View at Scopus
  5. A. Mazumder and S. A. Rosenberg, “Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2,” Journal of Experimental Medicine, vol. 159, no. 2, pp. 495–507, 1984. View at Google Scholar · View at Scopus
  6. S. A. Rosenberg, M. T. Lotze, and L. M. Muul, “A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone,” The New England Journal of Medicine, vol. 316, no. 15, pp. 889–897, 1987. View at Google Scholar · View at Scopus
  7. T. Takayama, T. Sekine, M. Makuuchi et al., “Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial,” The Lancet, vol. 356, no. 9232, pp. 802–807, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. I. G. H. Schmidt-Wolf, R. S. Negrin, H.-P. Kiem, K. G. Blume, and I. L. Weissman, “Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity,” Journal of Experimental Medicine, vol. 174, no. 1, pp. 139–149, 1991. View at Google Scholar · View at Scopus
  9. P.-H. Lu and R. S. Negrin, “A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency,” Journal of Immunology, vol. 153, no. 4, pp. 1687–1696, 1994. View at Google Scholar · View at Scopus
  10. R. D. Lopez, E. K. Waller, P.-H. Lu, and R. S. Negrin, “CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells,” Cancer Immunology, Immunotherapy, vol. 49, no. 11, pp. 629–640, 2000. View at Google Scholar · View at Scopus
  11. Y. C. Linn, L. C. Lau, and K. M. Hui, “Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts,” British Journal of Haematology, vol. 116, no. 1, pp. 78–86, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. C. Linn, S. K. J. Lau, B. H. Liu, L. H. Ng, H. X. Yong, and K. M. Hui, “Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell,” Immunology, vol. 126, no. 3, pp. 423–435, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. N. M. Alajez, J. Schmielau, M. D. Alter, M. Cascio, and O. J. Finn, “Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution,” Blood, vol. 105, no. 12, pp. 4583–4589, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. D. L. Barnd, M. S. Lan, R. S. Metzgar, and O. J. Finn, “Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 18, pp. 7159–7163, 1989. View at Google Scholar · View at Scopus
  15. J. Magarian-Blander, P. Ciborowski, S. Hsia, S. C. Watkins, and O. J. Finn, “Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1,” Journal of Immunology, vol. 160, no. 7, pp. 3111–3120, 1998. View at Google Scholar · View at Scopus
  16. M. R. Verneris, M. Karami, J. Baker, A. Jayaswal, and R. S. Negrin, “Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells,” Blood, vol. 103, no. 8, pp. 3065–3072, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Pende, G. M. Spaggiari, S. Marcenaro et al., “Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Polio virus receptor (CD 155) and Nectin-2 (CD 112),” Blood, vol. 105, no. 5, pp. 2066–2073, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Galandrini, N. Albi, D. Zarcone, C. E. Grossi, and A. Velardi, “Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity,” European Journal of Immunology, vol. 22, no. 8, pp. 2047–2053, 1992. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Ruggeri, M. Capanni, M. Casucci et al., “Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation,” Blood, vol. 94, no. 1, pp. 333–339, 1999. View at Google Scholar · View at Scopus
  20. Y. C. Linn, S. M. Wang, and K. M. Hui, “Comparative gene expression profiling of cytokine-induced killer cells in response to acute myloid leukemic and acute lymphoblastic leukemic stimulators using oligonucleotide arrays,” Experimental Hematology, vol. 33, no. 6, pp. 671–681, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. I. G. H. Schmidt-Wolf, P. Lefterova, V. Johnston et al., “Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells,” Cellular Immunology, vol. 169, no. 1, pp. 85–90, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Hoyle, C. D. Bangs, P. Chang, O. Kamel, B. Mehta, and R. S. Negrin, “Expansion of Philadelphia chromosome-negative CD3+CD56+ cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice,” Blood, vol. 92, no. 9, pp. 3318–3327, 1998. View at Google Scholar · View at Scopus
  23. C. Scheffold, K. Brandt, V. Johnston et al., “Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia,” Bone Marrow Transplantation, vol. 15, no. 1, pp. 33–39, 1995. View at Google Scholar · View at Scopus
  24. M. Kornacker, G. Moldenhauer, M. Herbst et al., “Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-?,” International Journal of Cancer, vol. 119, no. 6, pp. 1377–1382, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Lefterova, F. Schakowski, P. Buttgereit, C. Scheffold, D. Huhn, and I. G. H. Schmidt-Wolf, “Expansion of CD3+CD56+ cytotoxic cells from patients with chronic lymphocytic leukemia: in vitro efficacy,” Haematologica, vol. 85, no. 10, pp. 1108–1109, 2000. View at Google Scholar · View at Scopus
  26. A. Märten, S. Renoth, M. von Lilienfeld-Toal et al., “Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells,” Haematologica, vol. 86, no. 10, pp. 1029–1037, 2001. View at Google Scholar · View at Scopus
  27. C. Ziske, A. Märten, B. Schöttker et al., “Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9,” Molecular Therapy, vol. 3, no. 1, pp. 54–60, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Nagaraj, C. Ziske, and I. G. H. Schmidt-Wolf, “Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer,” Genetic Vaccines and Therapy, vol. 2, no. 1, article 12, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Edinger, T. J. Sweeney, A. A. Tucker, A. B. Olomu, R. S. Negrin, and C. H. Contag, “Noninvasive assessment of tumor cell proliferation in animal models,” Neoplasia, vol. 1, no. 4, pp. 303–310, 1999. View at Google Scholar · View at Scopus
  30. T. J. Sweeney, V. Mailänder, A. A. Tucker et al., “Visualizing the kinetics of tumor-cell clearance in living animals,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 21, pp. 12044–12049, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Edinger, Y.-A. Cao, M. R. Verneris, M. H. Bachmann, C. H. Contag, and R. S. Negrin, “Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging,” Blood, vol. 101, no. 2, pp. 640–648, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. M. R. Verneris, M. Ito, J. Baker, A. Arshi, R. S. Negrin, and J. A. Shizuru, “Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma,” Biology of Blood and Marrow Transplantation, vol. 7, no. 10, pp. 532–542, 2001. View at Google Scholar · View at Scopus
  33. J. Baker, M. R. Verneris, M. Ito, J. A. Shizuru, and R. S. Negrin, “Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production,” Blood, vol. 97, no. 10, pp. 2923–2931, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Nishimura, J. Baker, A. Beilhack et al., “In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity,” Blood, vol. 112, no. 6, pp. 2563–2574, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. J. K. Chan, C. A. Hamilton, M. K. Cheung et al., “Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study,” Clinical Cancer Research, vol. 12, no. 6, pp. 1859–1867, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. M. R. Verneris, A. Arshi, M. Edinger et al., “Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells,” Clinical Cancer Research, vol. 11, no. 12, pp. 4561–4570, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. V. Marin, E. Dander, E. Biagi et al., “Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy,” Experimental hematology., vol. 34, no. 9, pp. 1219–1229, 2006. View at Google Scholar · View at Scopus
  38. S. H. Thorne, R. S. Negrin, and C. H. Contag, “Synergistic antitumor effects of immune cell-viral biotherapy,” Science, vol. 311, no. 5768, pp. 1780–1784, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. J. C. Alvarnas, Y.-C. Linn, E. G. Hope, and R. S. Negrin, “Expansion of cytotoxic CD3+CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation,” Biology of Blood and Marrow Transplantation, vol. 7, no. 4, pp. 216–222, 2001. View at Google Scholar · View at Scopus
  40. M. Introna, M. Franceschetti, A. Ciocca et al., “Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation,” Bone Marrow Transplantation, vol. 38, no. 9, pp. 621–627, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. I. G. H. Schmidt-Wolf, S. Finke, B. Trojaneck et al., “Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-1 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma,” British Journal of Cancer, vol. 81, no. 6, pp. 1009–1016, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Leemhuis, S. Wells, C. Scheffold, M. Edinger, and R. S. Negrin, “A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma,” Biology of Blood and Marrow Transplantation, vol. 11, no. 3, pp. 181–187, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Arai, K. Sheehan, S. Moore et al., “Autologous cytokine-induced killer cells as post-transplant cellular immunotherapy,” ASH Annual Meeting Abstracts, vol. 110, no. 11, p. 580, 2007. View at Google Scholar
  44. H. Jiang, K. Y. Liu, C. R. Tong, B. Jiang, and D. P. Lu, “The efficacy of chemotherapy in combination with auto-cytokine-induced killer cells in acute leukemia,” Zhonghua Nei Ke Za Zhi, vol. 44, no. 3, pp. 198–201, 2005. View at Google Scholar · View at Scopus
  45. J. Jiang, N. Xu, C. Wu et al., “Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells,” Anticancer Research, vol. 26, no. 3B, pp. 2237–2242, 2006. View at Google Scholar · View at Scopus
  46. D.-S. Weng, J. Zhou, Q.-M. Zhou et al., “Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas,” Journal of Immunotherapy, vol. 31, no. 1, pp. 63–71, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Wang, F. J. Zhou, Q. J. Wang et al., “Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma—a report of ten cases,” Ai Zheng, vol. 25, no. 5, pp. 625–630, 2006. View at Google Scholar · View at Scopus
  48. G. G. Laport, K. Sheehan, R. Lowsky et al., “Cytokine induced killer (CIK) cells as post-transplant immunotherapy following allogeneic hematopoietic cell transplantation,” ASH Annual Meeting Abstracts, vol. 108, no. 11, p. 412, 2006. View at Google Scholar
  49. M. Introna, G. Borleri, E. Conti et al., “Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study,” Haematologica, vol. 92, no. 7, pp. 952–959, 2007. View at Publisher · View at Google Scholar · View at Scopus